Higher serum activin A predicts adverse outcomes in AI-refractory hormone receptor-positive metastatic breast cancer in the Phase III BOLERO-2 trial (everolimus + exemestane vs exemestane alone)
Year: 2026
Type: preprint
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.6460521
Authors: Laura K. Krecko, Ayesha Ali, Meghan Hupp, Ashley Kang, Hyma Vani Polimera, Suhail M. Ali, Kim Leitzel, Eric Marks, Albert Reisling, Scott Hofsess, Robert Sweetman, Steve Nowmos, Daniel S. Rooks, Cristina Truica, Monali Vasekar, Vinod Nagabhairu, Angelique Richardson, Ashok Maddukuri, Prashanth Moku, Karen Muindi, Maren May, Gabriel Hortobagyi, Jose Baselga, A. Lipton
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7140308446